A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of each individual dose of esketamine
nasal spray, 56 milligram (mg) and 84 mg, compared with placebo nasal spray in improving
depressive symptoms in participants with treatment resistant depression (TRD), as assessed by
the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score
from Day 1 (prerandomization) to the end of the 4 week double-blind treatment phase (Day 28).